About Esperion Therapeutics, Inc. - Common Stock (ESPR)
Esperion Therapeutics is a biotechnology company focused on developing and commercializing innovative therapies for cardiovascular diseases. The company specializes in creating oral medications aimed at lowering cholesterol levels, with a particular emphasis on treating patients with elevated low-density lipoprotein cholesterol (LDL-C). Esperion's research and development efforts are centered around understanding the underlying mechanisms of heart disease and providing effective solutions that can significantly reduce cardiovascular risk. Through its commitment to scientific advancement and patient care, Esperion strives to enhance the treatment landscape for individuals with hyperlipidemia and related conditions. Read More
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Esperion Therapeutics, Inc. (NASDAQ: ESPR) to funds managed by ARCHIMED for $3.16 per share in cash and the right to participate in contingent milestone payments.
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty financing agreement under which certain funds managed by Athyrium Capital Management (the “Athyrium Funds”) will acquire 100% of Esperion’s royalty interest, held by Esperion pursuant to that certain License and Collaboration Agreement, dated as of April 17, 2020, as amended, by and among Esperion and Otsuka Pharmaceutical Co., Ltd (“Otsuka”), of Otsuka’s net sales of bempedoic acid products in Japan from and after January 1, 2026, together with related regulatory and commercial milestone payments, subject to a cap.
– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth –
ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET.
– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia –
Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis.
– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth –
ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026.
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET.
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025.
– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits –
